 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 2186-------------------------------------------------- |
|
Ocrevus the "most impressive drug launch of 2017" (Bio |
|
PharmaDive) |
|
By: agate Date: August 17, 2018, 9:53 am |
|
--------------------------------------------------------- |
|
Back in December 2017, BioPharmaDive regarded Ocrevus as the |
|
most impressive drug launch of 2017--"Most Impressive Drug |
|
Launch: Roche's Ocrevus." |
|
https://www.biopharmadive.com/news/most-impressive-drug-launch-roche-ocrevus-20… |
|
#Post#: 2253-------------------------------------------------- |
|
Ocrevus called a blockbuster drug |
|
By: agate Date: October 18, 2018, 7:58 pm |
|
--------------------------------------------------------- |
|
Ocrevus is turning out to be a blockbuster drug, according to |
|
PMLive, a pharmaceutical news Website (October 17, 2018): |
|
[quote] |
|
[font=inherit]Sales of Roche�s new multiple sclerosis therapy |
|
Ocrevus more than tripled in the first nine months of 2018, |
|
helping to compensate for the loss of patent protection on its |
|
older blockbuster drugs.[/font] |
|
[font=inherit]Ocrevus |
|
http://www.pmlive.com/pharma_news/roches_ocrevus_is_first_primary_progressive_m… |
|
/>(ocrelizumab) only made its debut in the US last year, but has |
|
already vaulted itself to blockbuster status, with sales up 238% |
|
to CHF 1.67bn ($1.68bn). Roche said it has seen strong uptake in |
|
both relapsing-remitting and primary progressive forms of MS in |
|
the US, which still accounts for more than 90% of the drug�s |
|
sales, with Europe gaining traction with sales of CHF 130m. |
|
[/quote][font=inherit]CHF = Swiss francs[/font][size=15px] |
|
***************************************************** |
